Last reviewed · How we verify

Urotol® — Competitive Intelligence Brief

Urotol® (Urotol®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic receptor antagonist. Area: Urology.

phase 3 Muscarinic receptor antagonist M3 muscarinic receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

Urotol® (Urotol®) — R-Pharm. Urotol is a muscarinic receptor antagonist used to treat overactive bladder.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Urotol® TARGET Urotol® R-Pharm phase 3 Muscarinic receptor antagonist M3 muscarinic receptor
Glycopyrrolate + Formoterol Glycopyrrolate + Formoterol Chiesi Farmaceutici S.p.A. marketed Long-acting muscarinic antagonist (LAMA) + long-acting beta-2 agonist (LABA) combination M3 muscarinic receptor; beta-2 adrenergic receptor
Solifenacin with vaginal estrogen cream Solifenacin with vaginal estrogen cream Mackay Memorial Hospital marketed Anticholinergic agent (solifenacin) + topical estrogen (vaginal cream) M3 muscarinic receptor (solifenacin); estrogen receptor (vaginal estrogen)
Solifenacin + Mirabegron Solifenacin + Mirabegron University of Aarhus marketed Antimuscarinic + Beta-3 adrenergic agonist combination M3 muscarinic receptor (solifenacin) and beta-3 adrenergic receptor (mirabegron)
Tolterodine Tartrate ER Tolterodine Tartrate ER University of California, San Francisco marketed Muscarinic receptor antagonist M2 and M3 muscarinic receptors
albuterol plus tiotropium albuterol plus tiotropium IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy marketed Combination bronchodilator (SABA + LAMA) Beta-2 adrenergic receptor (albuterol); M3 muscarinic receptor (tiotropium)
Umeclidinium/Vilanterol 62.5/25 mcgs Umeclidinium/Vilanterol 62.5/25 mcgs National Institute of Respiratory Diseases, Mexico marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic receptor antagonist class)

  1. KYU-SUNG LEE · 1 drug in this class
  2. Oupushifang Pharmaceutical Technology Co., Ltd. · 1 drug in this class
  3. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
  4. R-Pharm · 1 drug in this class
  5. University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Urotol® — Competitive Intelligence Brief. https://druglandscape.com/ci/urotol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: